Immunotherapy News and Research

Latest Immunotherapy News and Research

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

DSM Pharmaceutical Products, the custom manufacturing business of Royal DSM N.V., and Agennix AG have signed a new contract under which DSM will continue to manufacture talactoferrin for Agennix at commercial levels.

13 Mar 2012

Positive phase II trial results from Circassia's ragweed allergy therapy

Circassia Ltd, a specialty biopharmaceutical company focused on allergy, today announced that its ragweed allergy therapy has achieved positive results in a key phase II clinical trial.

8 Mar 2012

Combining radiation therapy with ipilimumab shows promise against melanoma

Research published today in the New England Journal of Medicine by scientists at the Ludwig Institute for Cancer Research (LICR) and Memorial Sloan-Kettering Cancer Center (MSKCC) showed that combining targeted radiation therapy with immunotherapy (ipilimumab), fostered a strong immune response and a favorable clinical outcome in a patient with melanoma, the most dangerous form of skin cancer.

8 Mar 2012

Celldex fourth quarter net loss increases to $12.7 million

Celldex Therapeutics, Inc. today reported financial results for the fourth quarter and the year ended December 31, 2011.

8 Mar 2012

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Intellect Neurosciences, Inc., a biopharmaceutical company engaged in the discovery and development of disease-modifying therapeutic agents for the treatment of Alzheimer's and other neurological diseases announced today that it received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for patent claims covering the company's ANTISENILIN monoclonal antibody platform technology for the treatment and prevention of Alzheimer's disease.

7 Mar 2012

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Researchers from the Perelman School of Medicine at the University of Pennsylvania report this month in Cancer Research a universal approach to personalized cancer therapy based on T cells. It is the first time a system for making an adaptable, engineered T-cell to attack specific tumor types has been proposed, depending on which abnormal proteins, called antigens, are expressed by individual patients' tumor cells.

6 Mar 2012

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck, known as MSD outside the United States and Canada, today announced the results from a Phase III clinical study of its investigational allergy immunotherapy tablet (AIT) for ragweed pollen.

6 Mar 2012

Merck announces success of pill against ragweed allergy

Merck & Co. announced Monday that their experimental allergy tablet reduced allergic reactions to ragweed and helped patients use less medication to treat their symptoms.

5 Mar 2012

DBV receives FDA Fast Track Designation for Viaskin Peanut clinical development program

DBV Technologies announced today that it has received "Fast Track Designation" for the Clinical Development Program of its Viaskin Peanut, a product designed for the treatment by Epicutaneous Immunotherapy (EPIT) of patients with peanut allergy.

28 Feb 2012

Opexa 2011 net loss increases to $5,968,448

Opexa Therapeutics, Inc., a biotechnology company developing a novel T-cell therapy for multiple sclerosis (MS), today reported financial results for the year ended December 31, 2011 and provided an overview of corporate developments during the last year.

27 Feb 2012

Dendreon 2011 product revenue increases to $213.5M

Dendreon Corporation today reported results for the year and quarter ended December 31, 2011. Product revenue for the year ended December 31, 2011 was $213.5 million compared to $48 million for the year ended December 31, 2010. Product revenue for the fourth quarter of 2011 was $77 million compared to $25 million for the quarter ended December 31, 2010.

27 Feb 2012

Skin cancer drug may prolong survival in advanced cases: Study

Researchers say 132 patients in the U.S. and Australia who were given the drug vemurafenib gained several extra months of life. The study published in the New England Journal of Medicine found that those on the drug lived an average of 16 months, compared with nine months on conventional treatment.

26 Feb 2012

Five things that can aggravate suffering of people with spring allergies

Fruits and veggies, air filters, spring breezes, procrastination and self-medication - each can delay relief from a stuffy nose, sneezing, sniffling or other symptoms if you're one of the more than 35 million Americans who suffer from seasonal allergies.

24 Feb 2012

Celldex announces pricing of underwritten public offering of common stock

Celldex Therapeutics, Inc. today announced the pricing of an underwritten public offering of 10,500,000 shares of its common stock, offered at a price to the public of $3.85 per share for an aggregate offering of $40,425,000 of common stock.

24 Feb 2012

University of Pennsylvania, IMUC enter license agreement for dendritic-cell production method

ImmunoCellular Therapeutics today announced that it has entered into an agreement with the University of Pennsylvania under which University of Pennsylvania has granted the Company an exclusive, worldwide license for a patent pending technology for the production of high-activity dendritic cells.

21 Feb 2012

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Blocking autophagy -- the process of "self-eating" within cells -- is turning out to be a viable way to enhance the effectiveness of a wide variety of cancer treatments.

19 Feb 2012

Four new drugs can extend survival and prognosis of prostate cancer

After a decade and a half of near stagnation, four new drugs could help make advanced prostate cancer a chronic illness instead of a terminal disease, a leading Colorado prostate cancer expert says.

17 Feb 2012

Combination of therapeutic cancer vaccines and chemotherapy shows promise

Therapeutic cancer vaccines, which stimulate the body's immune system to target and destroy cancer cells, are being used in combination with conventional chemotherapy with growing success, as described in several illuminating articles in Cancer Biotherapy and Radiopharmaceuticals, a peer-reviewed journal from Mary Ann Liebert, Inc.

16 Feb 2012

Epigenetic mechanisms maintain tolerance in T cells specific for self antigens

At the most basic level, the immune system must distinguish self from non-self, that is, it must discriminate between the molecular signatures of invading pathogens (non-self antigens) and cellular constituents that usually pose no risk to health (self-antigens).

14 Feb 2012

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

OncoSec Medical Incorporated, which is developing its advanced-stage OncoSec Medical System (OMS) ElectroOncology therapies to treat solid tumor cancers, today announced that physicians at the University of Washington and Seattle Cancer Care Alliance in conjunction with the Fred Hutchinson Cancer Center, have treated several patients in an open-label Phase II clinical trial evaluating OncoSec's OMS ElectroImmunotherapy for the treatment of Merkel cell carcinoma.

13 Feb 2012

Immunotherapy News and Research

Latest Immunotherapy News and Research

Agennix, DSM sign new contract to manufacture talactoferrin for NSCLC

Positive phase II trial results from Circassia's ragweed allergy therapy

Combining radiation therapy with ipilimumab shows promise against melanoma

Celldex fourth quarter net loss increases to $12.7 million

Intellect Neurosciences receives U.S. patent allowance for ANTISENILIN to treat AD

Penn-led team develops universal approach to personalized cancer therapy based on T cells

Merck announces results from AIT Phase III clinical study for ragweed allergy

Merck announces success of pill against ragweed allergy

DBV receives FDA Fast Track Designation for Viaskin Peanut clinical development program

Opexa 2011 net loss increases to $5,968,448

Dendreon 2011 product revenue increases to $213.5M

Skin cancer drug may prolong survival in advanced cases: Study

Five things that can aggravate suffering of people with spring allergies

Celldex announces pricing of underwritten public offering of common stock

University of Pennsylvania, IMUC enter license agreement for dendritic-cell production method

Penn oncologist to discuss role of autophagy in fighting cancer at AAAS annual meeting

Four new drugs can extend survival and prognosis of prostate cancer

Combination of therapeutic cancer vaccines and chemotherapy shows promise

Epigenetic mechanisms maintain tolerance in T cells specific for self antigens

OncoSec to commence OMS ElectroImmunotherapy Phase II trial in MCC

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in